| Cytoskeletal tension inhibits Hippo signaling through an Ajuba-Warts complex C Rauskolb, S Sun, G Sun, Y Pan, KD Irvine Cell 158 (1), 143-156, 2014 | 366 | 2014 |
| CDK7 inhibition potentiates genome instability triggering anti-tumor immunity in small cell lung cancer H Zhang, CL Christensen, R Dries, MG Oser, J Deng, B Diskin, F Li, Y Pan, ... Cancer cell 37 (1), 37-54. e9, 2020 | 167 | 2020 |
| Differential growth triggers mechanical feedback that elevates Hippo signaling Y Pan, I Heemskerk, C Ibar, BI Shraiman, KD Irvine Proceedings of the National Academy of Sciences 113 (45), E6974-E6983, 2016 | 142 | 2016 |
| ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer J Deng, A Thennavan, I Dolgalev, T Chen, J Li, A Marzio, JT Poirier, ... Nature cancer 2 (5), 503-514, 2021 | 76 | 2021 |
| Generation of genetically engineered mouse lung organoid models for squamous cell lung cancers allows for the study of combinatorial immunotherapy J Hai, H Zhang, J Zhou, Z Wu, T Chen, E Papadopoulos, CM Dowling, ... Clinical Cancer Research 26 (13), 3431-3442, 2020 | 50 | 2020 |
| The dynamics of Hippo signaling during Drosophila wing development Y Pan, H Alégot, C Rauskolb, KD Irvine Development 145 (20), dev165712, 2018 | 47 | 2018 |
| Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib H Han, S Li, T Chen, M Fitzgerald, S Liu, C Peng, KH Tang, S Cao, ... Cancer research 81 (20), 5311-5324, 2021 | 36 | 2021 |
| Squamous cell lung cancer: Current landscape and future therapeutic options SCM Lau, Y Pan, V Velcheti, KK Wong Cancer Cell 40 (11), 1279-1293, 2022 | 32 | 2022 |
| Functional identification of a novel 14-3-3 epsilon splicing variant suggests dimerization is not necessary for 14-3-3 epsilon to inhibit UV-induced apoptosis D Han, G Ye, T Liu, C Chen, X Yang, B Wan, Y Pan, L Yu Biochemical and Biophysical Research Communications 396 (2), 401-406, 2010 | 31 | 2010 |
| Recent advances in preclinical models for lung squamous cell carcinoma Y Pan, H Han, KE Labbe, H Zhang, KK Wong Oncogene 40 (16), 2817-2829, 2021 | 30 | 2021 |
| Epigenetic CRISPR Screens Identify Npm1 as a Therapeutic Vulnerability in Non–Small Cell Lung Cancer F Li, WL Ng, TA Luster, H Hu, VO Sviderskiy, CM Dowling, ... Cancer research 80 (17), 3556-3567, 2020 | 21 | 2020 |
| KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition Y Pan, H Han, H Hu, H Wang, Y Song, Y Hao, X Tong, AS Patel, ... Cancer Cell 41 (1), 88-105. e8, 2023 | 20 | 2023 |
| Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer Y Pan, Y Hao, H Han, T Chen, H Ding, KE Labbe, E Shum, K Guidry, H Hu, ... Journal for immunotherapy of cancer 10 (9), 2022 | 6 | 2022 |
| Near-infrared nuclear markers for Drosophila imaging Y Pan, C Rauskolb, KD Irvine Micropublication Biology 2022, 2022 | 1 | 2022 |
| Transiently secretory expression of DsRed driven by sericin promoter with the signal peptide sequence of fibroin H chain of Bombyx mori. PY Peng Yun, PYW Pan YuanWang, QYY Qian YanYan, ... | 1 | 2009 |
| Therapeutic targeting of kmt2d mutant lung squamous cell carcinoma through rtk-ras signaling inhibition K Wong, Y Pan, H Han, H Zhang US Patent App. 17/935,915, 2023 | | 2023 |
| 1661P Antitumor efficacy and immune profiling of the mouse ortholog of nemvaleukin alfa, a novel engineered IL-2 fusion protein, in an orthotopic mouse model of small cell lung … Y Pan, H Zhang, T Chen, H Ding, H Han, C Almonte, KE Labbe, S Nguyen, ... Annals of Oncology 32, S1169, 2021 | | 2021 |
| Overcome LKB1 mutated cancer resistance to anti-PD1 treatment J Deng, A Thennavan, Y Pan, I Dolgalev, T Chen, H Silver, M Harris, ... Cancer Research 79 (13_Supplement), 3223-3223, 2019 | | 2019 |
| Mechanical Control of Tissue Growth through Hippo Signaling Y Pan Rutgers The State University of New Jersey, School of Graduate Studies, 2018 | | 2018 |
